diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-6232diaendo-6232Research ArticleСтатьиArticlesРезультаты открытой наблюдательной программы DIAMONDThe results of open observational trial DIAMONDШестаковаМарина ВладимировнаShestakovaMarina Vladimirovna-ВикуловаОльга КонстантиновнаVikulovaOlga Konstantinovnaolga-vikulova@yandex.ruФГУ Эндокринологический научный центр, МоскваEndocrinology Research Centre, Moscow201115092011143№3 (2011)96102Copyright © Шестакова М.В., Викулова О.К., 20112011Шестакова М.В., Викулова О.К.Shestakova M.V., Vikulova O.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6232сахарный диабет 2 типагипогликемияДиабетон МВисследование ADVANCEtype 2 diabetes mellitushypoglycemiaDiamicron MBADVANCE trialReferencesШестакова М.В. Из доклада «Новые рекомендации по терапии СД2 в России». Обучающий курс Joslin Diabetes Center и ЭНЦ МЗРФ. - М., 25 мая 2011 г.Шестакова М.В. Из доклада «Новые рекомендации по терапии СД2 в России». Обучающий курс Joslin Diabetes Center и ЭНЦ МЗРФ. - М., 25 мая 2011 г.Gribble F.M., Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions // J. Diabetes Complications. - 2003. - № 17. - Р. 11-15.Gribble F.M., Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions // J. Diabetes Complications. - 2003. - № 17. - Р. 11-15.Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kem - pler P., Kvapil M., Novials A., Rottiers R., Rutten G. E. H. M. and Shaw K. M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients // European Journal of Clinical Investigation. - 2004. - № 34. - Р. 535-542.Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kem - pler P., Kvapil M., Novials A., Rottiers R., Rutten G. E. H. M. and Shaw K. M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients // European Journal of Clinical Investigation. - 2004. - № 34. - Р. 535-542.Tessier D., Dawson K., Tetrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly // Diabet Med. - 1994. - № 11. - Р. 974-980.Tessier D., Dawson K., Tetrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly // Diabet Med. - 1994. - № 11. - Р. 974-980.Veitch P.C., Clifton-Bligh R.J. Long-acting sulfonylureas - long-acting gypoglycaemia // Med. J. Aust. - 2004. - № 180. - Р. 84-85.Veitch P.C., Clifton-Bligh R.J. Long-acting sulfonylureas - long-acting gypoglycaemia // Med. J. Aust. - 2004. - № 180. - Р. 84-85.Patel A., MacMahon S., Chalmers J., Neal B. et al. The ADVANCE Collaborative GrouP. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2560-2572.Patel A., MacMahon S., Chalmers J., Neal B. et al. The ADVANCE Collaborative GrouP. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2560-2572.Drouin1 P., Standl E. for the Diamicron MR Study GrouP. Gliclazide modified release*: results of a 2-year study in patients with type 2 diabetes // Diabetes, Obesity and Metabolism. - 2004. - № 6. - Р. 414-421.Drouin1 P., Standl E. for the Diamicron MR Study GrouP. Gliclazide modified release*: results of a 2-year study in patients with type 2 diabetes // Diabetes, Obesity and Metabolism. - 2004. - № 6. - Р. 414-421.Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. et al. The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2545-2559.Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. et al. The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2545-2559.Duckworth W., Abraira C., Mortiz T., Reda D. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. - 2009. - № 360. - Р. 129-139.Duckworth W., Abraira C., Mortiz T., Reda D. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. - 2009. - № 360. - Р. 129-139.Zoungas S., Chalmers J., Kengne A.P., Pillai A., Billot L., de Galan B., Marre M., Neal B., Harrap S., Poulter N., Patel A. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial // Diab. Res. Clin. Pract. - 2010. - № 89. - Р. 126-133. doi:10.1016/j.diabres. 2010.05.012.Zoungas S., Chalmers J., Kengne A.P., Pillai A., Billot L., de Galan B., Marre M., Neal B., Harrap S., Poulter N., Patel A. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial // Diab. Res. Clin. Pract. - 2010. - № 89. - Р. 126-133. doi:10.1016/j.diabres. 2010.05.012.Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events // Diabetes Care. - 2010. - № 33(6). - Р. 1389-1394.Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events // Diabetes Care. - 2010. - № 33(6). - Р. 1389-1394.Skyler J.S., Bergenstal R., Bonow R.O., Buse J. et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Tials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association // Circulation. - 2009. - № 119. - Р. 351-357.Skyler J.S., Bergenstal R., Bonow R.O., Buse J. et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Tials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association // Circulation. - 2009. - № 119. - Р. 351-357.Klepzig H., Kober G., Matter C. et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide // Eur. Heart J. - 1999. - № 20. - Р. 439-446.Klepzig H., Kober G., Matter C. et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide // Eur. Heart J. - 1999. - № 20. - Р. 439-446.Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischemic preconditioning or nicorandil is not blocked by gliclazide // Cardiovasc Drugs Ther. - 2004. - № 18. - Р. 113-119.Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischemic preconditioning or nicorandil is not blocked by gliclazide // Cardiovasc Drugs Ther. - 2004. - № 18. - Р. 113-119.Thisted H., Johnsen S.P., Rungby J. Sulfonylureas and the risk of myocardial infarction // Metabolism. - 2006. - № 55. - S16-S19.Thisted H., Johnsen S.P., Rungby J. Sulfonylureas and the risk of myocardial infarction // Metabolism. - 2006. - № 55. - S16-S19.Johnsen S.P., Monster T.B., Olsen M.L. et al. Risk and short-term prognosis of myocardial infarction among users of antidibetic drugs // Am. J. Ther. - 2006. - № 13. - Р. 134-140.Johnsen S.P., Monster T.B., Olsen M.L. et al. Risk and short-term prognosis of myocardial infarction among users of antidibetic drugs // Am. J. Ther. - 2006. - № 13. - Р. 134-140.Monami M., Balzi D., Lamanna C., Barchielli et al. Are sulfonylureas all the same? A cohort study on cardiovascular and cancer related mortality // Diabetes Metab. Res. Rev. - 2007. - № 23. - Р. 479-484.Monami M., Balzi D., Lamanna C., Barchielli et al. Are sulfonylureas all the same? A cohort study on cardiovascular and cancer related mortality // Diabetes Metab. Res. Rev. - 2007. - № 23. - Р. 479-484.Monami M., Luzzzi C., Lamanna C. et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin // Diabetes Metab. Res. Rev. - 2006. - № 22. - Р. 477-482.Monami M., Luzzzi C., Lamanna C. et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin // Diabetes Metab. Res. Rev. - 2006. - № 22. - Р. 477-482.Khalangot M., Tronko M., Kravchenko V., Kovtun V. Glibenclamiderelated excess in total and ardiovascular mortality risks: data from large Ukrainian observational cohort study // Diabetes Res. Clin. Pract. - 2009. - № 86. - Р. 247-253.Khalangot M., Tronko M., Kravchenko V., Kovtun V. Glibenclamiderelated excess in total and ardiovascular mortality risks: data from large Ukrainian observational cohort study // Diabetes Res. Clin. Pract. - 2009. - № 86. - Р. 247-253.Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study // European Heart Journal. - 2011. - doi:10.1093/eurheartj/ehr077.Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study // European Heart Journal. - 2011. - doi:10.1093/eurheartj/ehr077.Gram J., Jespersen J. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients // Am. J. Med. - 1991. - № 90. - P. 62S-66S.Gram J., Jespersen J. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients // Am. J. Med. - 1991. - № 90. - P. 62S-66S.Zoungas S., Chalmers J., Patel A., et al. Intensive glucose control is renoprotective in type 2 diabetes: new analyses from ADVANCE. Abstracts of 46th annual meeting of the European Association for the Study of Diabetes, 2010 // Diabetologia. - 2010. - № 53(Suppl1). - S98.Zoungas S., Chalmers J., Patel A., et al. Intensive glucose control is renoprotective in type 2 diabetes: new analyses from ADVANCE. Abstracts of 46th annual meeting of the European Association for the Study of Diabetes, 2010 // Diabetologia. - 2010. - № 53(Suppl1). - S98.
The authors declare that there are no conflicts of interest present.